inc hold pt maintain hold rais pt expect chipotl
momentum continu believ gain price analyst stephen anderson full summari
cerecor inc buy pt divestitur bring focu turn toward high-valu pipelin analyst jason
inc buy pt build earli proof concept dry-amd addit posit data
present meet analyst jason mccarthi ph full summari
matina biopharma hold inc mtnb buy pt enact phase initi bring safer amphotericin
corpor event call maxim salesperson inform
horizon technolog financ corp hrzn cover diana ndr boston ceo rob pomeroy cfo
matina biopharma hold inc mtnb cover mccarthi ndr nyc ceo jerom jabbour tue oct
volitionrx limit vnrx cover mccarthi ndr dalla ceo cameron reynold tue oct
cerecor inc cover mccarthi ndr nyc ceo simon pedder jame harrel cfo miller
vice-president head discoveri stephen thoma tue
dynatron corpor dynt cover vendetti ndr nyc ceo brian baker vice-president corpor
california restaur tour habt host mon-tu
graham corpor cover sullivan ndr st loui cfo jeffrey glajch thu dec
graham corpor cover sullivan ndr kansa citi cfo jeffrey glajch fri dec
cover chokshi ndr philadelphia ceo jeff rosica fri
pure storag inc cover chokshi ndr san francisco presid dave hatfield tue dec
maintain hold rais pt expect chipotl
momentum continu believ gain price
maintain hold rate chipotl mexican grill though rais
price target ahead releas septemb
result close tuesday octob expect momentum
top-lin initi join somewhat favor commod cost
next quarter
leav in-lin ep estim unchang though rais
decemb ep estim vs street
avocado price eas recent week
also rais ep estim vs street
expect digit driven sale deliveri contribut comp growth
prior street top project gain
upwardli revis price target base new base
valuat year increas ep estim
revis ebitda model
leav in-lin ep estim unchang though rais
decemb ep estim avocado price
eas recent week updat model base unchang comp
estim vs street vs street
chang model sharp drop avocado price
occur sinc mid-summ push price less half mid-juli level
figur lesser extent expect relief price tomato
mexico reach agreement stave new tariff though agreement
increas inspect mute tariff relief estim tomato
avocado alon compris much cmg total food cost
also rais ep estim base
revis comp estim retrospect underestim speed
cmg custom adopt online/mobil order delivery/cat sale
believ contribut comp expect lap mid-
to-high-single-digit comp believ comp gain driven
increas tech-en sale estim approach sale year-
end june year-end increment
gain chipotl reward loyalti program gain five million member
sinc launch march deliveri cater estim
repres total sale increas implement chipotlan drive-
thru lane exist locat end expect
grow mani locat new reloc site year-end
anoth top-lin catalyst expect slight acceler unit
growth addit restaur repres net new unit growth
project pace restaur
construct cmg technolog push well current carn
asada marin skirt steak limited-tim offer lto current menu caution
investor overemphas potenti upsid new menu item
visit new york citi test kitchen last week found nacho quesadilla
ad back test menu prior test earlier year believ
manag continu test oper complex regard assembl
potenti broader roll-out
regard margin model restaurant-level ebitda margin
expans top margin expans project
believ cmg top-lin catalyst particularli push toward digit enabl
sale help boost restaurant-level product moreov
expect margin expans food cost line expect
benign year commod cost
expect buyback key compon ep growth end
million cash balanc sheet expect fund mix
new unit develop digit initi share buyback expect free
cash flow rise
compani lap restructur charg project manag resum
aggress buyback acceler buyback accord
revis model share buyback add increment ep
per share much per share figur
rule possibl compani initi dividend earli
expect use cash acceler unit growth modestli follow
buyback key risk outlook cmg share price remain high
pace share count reduct may mute even revers buyback
scale back option exercis case
even increas price target believ posit
price share thu recommend chase share
higher base yesterday close price share trade upwardli
revis ep estim revis ep estim
account cmg strong debt-fre balanc gener robust free
cash flow add forward ev/ebitda compon valuat methodolog
revis price target base revis ep estim
prior ep estim forward ev/
ebitda base model
click full note
build earli proof concept dry-amd addit
posit data present meet
lineag present new addit posit data cohort trial
opregen dry-amd age-rel macular degener american
academi ophthalmolog annual meet key take-away
data continu demonstr posit chang visual acuiti durabl
safeti also import consid data mean term
broader ophthalm space also valuat perspect
visual acuiti improv dry-amd letter rang
wet-amd therapi approv letter line earli
view realli data start show durabl respons treat
eye go month three patient cohort one patient
orbit month patient worth data durabl
safeti
consid approv therapi dry-amd data far
gene therapi ophthalm space small n-valu
soar valuat lineag cell therapi opregen
market capit under-valued view
opregen new data dry-amd new data report cohort on-going
phase trial dry-amd recal cohort includ patient impair vision
versu cohort use legal blind patient
patient target treat cohort data far
encourag improv visual acuiti measur earli treatment diabet
retinopathi scale etdr improv patient rang
letter patient month patient month patient
month patient month compar untreat
eye importantli fourth patient treat new orbit sd
thaw-and-inject tai formul repres realist modal
clinic next five patient plan enrol also dose use
orbit sd addit function improv anatom improv
presenc drusen materi improvements/restor ellipsoid zone
retin pigment epithelium rpe layer observ well slowdown
progress geograph atrophi let review aspect data
efficaci data demonstr continu efficaci term treat eye
view clearli gain improv compar untreat control eye
improv visual acuiti rang letter vs control
durabl patient month one month fourth first treat
orbit deliveri month still go durabl safeti
critic seen approach like gene therapi
clinic meaning key point consid dry-amd
benchmark yet term regul would consid approv howev
wet-amd side approv therapi letter line
less threshold far lineag opregen ballpark
far durabl
data point treatment effect base data cohort cohort
view clear therapeut effect opregen cell treat eye
vs control eye patient enrol optim import go
forward overal view lineag drug thu far difficult treat dry-
approv therapi
attract valuat earli proof concept data hand ophthalm
space seen billion dollar drug wet-amd valuat gene therapi
compani soar hand patient cell therapi
view compel data thu far patient lineag
dry-amd opportun aforement data taken context
dry-amd market drug approv indic despit repres
case comparison wet- market
substanti opportun dry-amd look best correct
visual acuiti bcva improv letter line typic cite
threshold clinic meaning improv use approv
wet-amd use benchmark fda approv drug
dry-amd set stone per se dry-amd opregen earli data
border number consid unmet need market size safeti
durabl also import consid patient treat follow-up
long three year unexpect observ addit new
orbit approach allow administr without punctur retina like
thu far cohort seen data patient last treat
use orbit recal patient less sever dry-amd legal
blind patient cohort cohort patient may experi
pronounc durabl improv vision thu far data compel
note rang wet-amd drug approv
said still earli regul set path forward approv dry-
therapi nonetheless take-away view lineag
earli proof concept cell therapi data come thu far appear
lineag drug
click full note
divestitur bring focu turn toward high-
announc sale commerci pediatr franchis ex
millipr profit product aytu bioscienc aytu nr
part deal aytu also retain pediatr salesforc creat
save per year
split up-front payment cash
aytu convert prefer stock aytu assumpt
debt factor up-front payment estim
balanc sheet cash stock
pediatr portfolio expect gener sell
deal bring non-dilut capit extend runway reduc expens
allow compani focu core program pipelin
seri
seri view repres shorter-term potenti high-
valu play asset pathway ultra-rar
pediatr diseas could also net one potenti
three prioriti review voucher pend product gain approv
nda file could come time-frame
earli stage asset could emerg next gen
noh neurogen orthostat hypertens pd well oh larger
indic comt inhibitor respect
rare pediatr diseas relat glycosyl product follow expedit
pathway hundr trial indic trial
small anticip launch first nda expect
month time-frame d-galactos replac
develop phosphoglucylmutas defici complet d-
mannos replac develop mannos phosphat isomeras defici
complet l-fucos replac develop leukocyt
adhes defici type ii ind file next mileston program
result cdg first studi on-going retrospect studi collect
natur histori treatment data support develop program
neurolog diseas pipelin
import due like shorter develop pathway potenti lucr
prioriti review voucher long term prospect orthostat hypotens
oh parkinson diseas pd true valu driver
patient popul initi indic potenti futur expans
respect demonstr posit data pd-relat neurogen
oh noh demonstr mmhg improv baselin beat
threshold clinic meaning improv hour
mmhg improv hour phase plan diabet oh
intradialyt hypotens plan drug
approv orthostat hypotens northera norepinephrin pro-drug act upon
adrenerg receptor midodrin vasoconstrictor hypertens agent
gener combin per year improv option
northera approv treatment pd-relat noh contain blackbox
warn supin hypertens increas risk stroke heart attack death
furthermor use limit patient norepinephrin defici
nmda receptor antagonist demonstr favor
safeti profil compar northera midodrin broader market
main issu short half-lif minut mean patient need dose
day may prefer patient due longer activ like fewer
model updat updat model sale pediatr busi
roll metric forward pt unchang
click full note
enact phase initi bring safer amphotericin
matina announc initi phase enact studi oral
amphotericin treatment fungal cryptococc mening studi
sponsor nation institut nih
take toxic ampho-terr amphotericin long
nicknam due sever toxic often use two week
intraven said ampho highli effect little/no clinic drug
resist tox issu limit use oral
formul leverag matina lipid-nanocryst technolog essenti
elimin toxic issu
prior nih work drug-resist candida infect
administ high dose week tox note drug-
resist candida captur media headlin sever month back
emerg candida auri invas infect ny time articl
interestingli bug literatur link postul
potenti emerg first new fungal diseas emerg climat
chang ampho attract anti-fung due broad activ
candida crypto well mold like aspergillu spp
enact timelines- data come first enact studi crypto
updat expect remaind
hiv cryptococcu mening enact studi
encochl oral amphotericin cryptococc mening trial
evalu induct mainten therapi hiv-pati
cryptococc mening life-threaten diseas caus neoforman
fungu commonli found soil spread via bird drop crypto infect mainli
affect peopl compromis immun system live hiv
among peopl hiv approxim new case cryptococc mening
occur world-wide year wherebi result death fda
grant orphan drug design treatment indic
open-label sequenti cohort studi compris two portion part
compris patient hiv without fungal infect determin maximum
toler dose within group wherea random part portion compris
hiv-infect patient cryptococc mening evalu oral vs
standard iv-administr amphotericin induct therapi qidp
track evalu safer amphotericin treatment within unmet
indic well includ prevent invas fungal infect ifi due
immunosuppress therapi treatment invas candidiasi aspergillu
safeti aspect overst amphotericin nicknam
ampho-terr due sever toxic particularli renal drug
littl known clinic drug resist effect deal
invas fungal diseas use limit due toxic standard intraven
iv amphotericin may use usual two week less tox
alon issu import note ifi patient develop secondari
condit co-morbid alreadi frail patient therefor
portion enact studi import recal prior work nih
studi drug-resist candidiasi patient deliv higher dose
iv administ week toxic expect
similar posit tox-profil demonstr crypto studi
click full note
maxim analyst coverag univers
sector coverag
care well
industri util
